Providing Hope in a helpless situation

HELPING PATIENTS SURVIVE CRITICAL ILLNESSES WORLDWIDE

CytoSorbents Corporation (NASDAQ: CTOS) is a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to control deadly inflammation in life-threatening conditions in the intensive care unit such as:

- Severe Sepsis and Septic Shock
- Traumatic Injury
- Acute Lung Injury and ARDS
- Burns and Smoke Inhalation
- Severe Acute Pancreatitis
- Influenza
- Cytokine Release Syndrome in Cancer Immunotherapy
- Histiocytosis
- Liver Failure
- Complications of Cardiac Surgery and Other Surgeries

Left unchecked, this body-wide inflammation can rapidly lead to organ failure, the leading cause of death in the ICU for which there are no effective therapies other than supportive care. Because of this, approximately 1 in every 3 patients will die, despite the best available medical treatment. And the costs are staggering, with the U.S. spending nearly $80-90 billion on critical care medicine each year.

CytoSorb® - Reducing the Fuel to the Fire
CytoSorb®, the company's flagship product, is a unique extracorporeal cytokine adsorber that reduces the "fuel to the fire" of inflammation by lowering a broad range of inflammatory mediators such as bacterial toxins and cytokines in the blood. By taking the "edge" off of the uncontrolled systemic inflammatory response syndrome (SIRS) yet keeping the immune system intact and functional, the goal of CytoSorb® therapy is to prevent or treat organ failure. The CytoSorb® cartridge works with standard hemodialysis machines in a hospital to rapidly purify a patient's blood outside of the body, recirculating the blood back into the body repeatedly, and has been used safely in more than 6,000 human treatments.

Regain Control: SIRS and Sepsis
CytoSorb® has been used to help save the lives of many patients. Physicians describe being able to stabilize and "regain control" of their rapidly deteriorating patients. The most common reported benefit of this immuno-modulatory therapy has been the stabilization of a patient's blood pressure in the face of severe hypotensive shock, with a weaning of vasopressor usage. Another observed benefit has been the improvement in respiratory function with weaning from mechanical ventilation, and the improvement in function of other organs. Other benefits have been to decrease a broad range of toxic substances in blood such as bacterial toxins, myoglobin, bilirubin, free hemoglobin, and many others.

EU Approved with Strong Partner and Govt Support
CytoSorb® is approved in the European Union and is distributed in more than 30 countries worldwide. CytoSorbents is strategically partnered with leading medical companies including Fresenius Medical Care - the world's largest dialysis company, Biocon Ltd - the largest biotechnology company in India, and one of the top 4 global cardiac surgery companies. CytoSorbents has also received pending support from DARPA (Defense Advanced Research Projects Agency), the US Army, the US Air Force, HHS, NHLBI, and NIH. CytoSorb® is not yet approved in the US, but is the subject of three FDA-approved IDE clinical trial protocols in cardiac surgery, trauma and rhabdomyolysis, and sepsis in the US, and more than 50 investigator-initiated studies in Europe and elsewhere.

CytoSorb® - Revolutionizing Critical Care Medicine
For more information, visit www.cytosorb.com and www.cytosorbents.com

The heart of the technology is based on biocompatible, highly porous polymer sorbent beads, roughly the size of grains of salt, which act like tiny sponges to capture and adsorb substances from whole blood.